Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Phase 2 Recruiting
188 enrolled
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Phase 2 Recruiting
160 enrolled
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Phase 2 Recruiting
111 enrolled
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Phase 2 Recruiting
285 enrolled
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
Phase 2 Recruiting
29 enrolled
Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma
Phase 2 Recruiting
18 enrolled
TROPHY U-01
Phase 2 Recruiting
827 enrolled 1 FDA
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Phase 2 Recruiting
80 enrolled
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Phase 2 Recruiting
130 enrolled
I-SPY
Phase 2 Recruiting
5,000 enrolled
Palbociclib and Pembrolizumab In Central Nervous System Metastases
Phase 2 Recruiting
45 enrolled
Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
Phase 2 Recruiting
23 enrolled
INTerpath-13
Phase 2 Recruiting
180 enrolled
GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
Phase 2 Recruiting
28 enrolled
Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia
Phase 2 Recruiting
25 enrolled
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
Phase 2 Recruiting
14 enrolled
MK-3475-01E
Phase 2 Recruiting
60 enrolled
Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC
Phase 2 Recruiting
26 enrolled
INTerpath-012
Phase 2 Recruiting
160 enrolled
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
Phase 2 Recruiting
105 enrolled
Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
Phase 2 Recruiting
57 enrolled
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC
Phase 2 Recruiting
80 enrolled
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Phase 2 Recruiting
332 enrolled
Surgical Pembro +/- Olaparib w TMZ for rGBM
Phase 2 Recruiting
78 enrolled
Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
Phase 2 Recruiting
20 enrolled
KIEO
Phase 2 Recruiting
30 enrolled
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Phase 2 Recruiting
110 enrolled
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
Phase 2 Recruiting
18 enrolled
DG-03
Phase 2 Recruiting
450 enrolled
Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Phase 2 Recruiting
47 enrolled
PRELUDE
Phase 2 Recruiting
44 enrolled
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
Phase 2 Recruiting
23 enrolled
Neo IRENIE
Phase 2 Recruiting
494 enrolled
IMPROEV
Phase 2 Recruiting
97 enrolled
MCC
Phase 2 Recruiting
15 enrolled
Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer
Phase 2 Recruiting
21 enrolled
MK-3475-01G
Phase 2 Recruiting
90 enrolled
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
Phase 2 Recruiting
34 enrolled
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Phase 2 Recruiting
78 enrolled
Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
Phase 2 Recruiting
35 enrolled
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
Phase 2 Recruiting
23 enrolled
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
Phase 2 Recruiting
20 enrolled
ALPINE: Maintenance Letrozole/Abemaciclib
Phase 2 Recruiting
32 enrolled
REDUCE
Phase 2 Recruiting
86 enrolled
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Phase 2 Recruiting
28 enrolled
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL
Phase 2 Recruiting
24 enrolled
Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC
Phase 2 Recruiting
15 enrolled
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
Phase 2 Recruiting
36 enrolled
Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer
Phase 2 Recruiting
21 enrolled
ZANGEA
Phase 2 Recruiting
80 enrolled